Skip to main content
SpringerLink
Log in

Linkage disequilibrium and haplotypes of five TP53 polymorphisms in oesophageal cancer patients

  • Research Article
  • Published:
Journal of Genetics Aims and scope Submit manuscript

Abstract

The aim of present study was to evaluate the linkage disequilibrium (LD) of p.R72P, PIN3 Ins16bp, p.P47S, p.R213R and r.13494g>a polymorphism of TP53 and their haplotypes association with oesophageal cancer risk in patients from Punjab, northwest India. A total of 466 samples, including 233 oesophageal cancer patients and 233 healthy individuals were analysed. Data analysis revealed the gender specific association. In female group, arginine–proline (RP) genotype (P = 0.08) and P allele (P = 0.07) of p.R72P polymorphism was marginally associated with increased risk of oesophageal cancer. A1A2 genotype (P = 0.06) and A2 allele (P = 0.07) of PIN3 Ins16bp polymorphism was marginally associated with decreased risk of oesophageal cancer in male group. A1A2–GA genotype combination (P = 0.04) of PIN3 and r.13494g>a polymorphisms was significantly associated with decreased risk of oesophageal cancer in male group. In female group, PP–GA genotype combination (P = 0.02) of p.R72P and r.13494g>a polymorphisms and RP–A1A1–GG genotype combination (P = 0.04) of p.R72P, PIN3 and r.13494g>a polymorphisms was significantly associated with increased risk of oesophageal cancer. We observed moderate LD between two intronic polymorphisms PIN3 Ins16bp and r.13494g>a (D′ = 0.90; r2 = 0.68). Haplotype analysis revealed that none of the haplotype combination was associated with oesophageal cancer risk when both the genders were considered. Stratification on the basis of gender showed that P-A2-P-A-A haplotype of p.R72P, PIN3 Ins16bp, p.P47S, p.R213R and r.13494g>a polymorphisms was marginally associated with reduced oesophageal cancer risk in male group (P = 0.08). Replication of these findings in independent cohorts may be insightful for the role of TP53 in oesophageal cancer pathogenesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Similar content being viewed by others

References

  • Barnoud T., Budina-Kolomets A., Basu S., Leu J. I., Good M., Kung C. P. et al. 2018 Tailoring Chemotherapy for the African-centric S47 variant of TP53. Cancer Res. 78, 5694–5705.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Basu S., Barnoud T., Kung C. P., Reiss M. and Murphy M. E. 2016 The African-specific S47 polymorphism of p53 alters chemosensitivity. Cell Cycle 15, 2557–2560.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Bergamaschi D., Gasco M., Hiller L., Sullivan A., Syed N., Trigiante G. et al. 2003 p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3, 387–402.

    CAS  PubMed  Google Scholar 

  • Buyru N., Altinisik J., Demokan S. and Dalay N. 2007 p53 genotypes and haplotypes associated with risk of breast cancer. Cancer Detect. Prev. 31, 207–213.

    CAS  PubMed  Google Scholar 

  • Cao Z., Song J. H., Park Y. K., Maeng E. J., Nam S. W., Lee J. Y. et al. 2009 The p53 codon 72 polymorphism and susceptibility to colorectal cancer in Korean patients. Neoplasma 56, 114–118.

    CAS  PubMed  Google Scholar 

  • Davis R. L., Homer V. M., George P. M. and Brennan S. O. 2009 A deep intronic mutation in FGB creates a consensus exonic splicing enhancer motif that results in afibrinogenemia caused by aberrant mRNA splicing, which can be corrected in vitro with antisense oligonucleotide treatment. Hum. Mutat. 30, 221–227.

    CAS  PubMed  Google Scholar 

  • Dumont P., Leu J. I., Della Pietra A. C III, George D. L. and Murphy M. 2003 The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33, 357–365.

    CAS  PubMed  Google Scholar 

  • Furihata M., Takeuchi T., Matsumoto M., Kurabayashi A., Ohtsuki Y., Terao N. et al. 2002 p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract. Clin. Cancer Res. 8, 1192–1195.

    CAS  PubMed  Google Scholar 

  • Garcia-Closas M., Kristensen V., Langerød A., Qi Y., Yeager M., Burdett L. et al. 2007 Common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer. Int. J. Cancer 121, 2532–2538.

    CAS  PubMed  Google Scholar 

  • Gemignani F., Moreno V., Landi S., Moullan N., Chabrier A., Gutiérrez-Enríquez S. et al. 2004 A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 23, 1954–1956.

    CAS  PubMed  Google Scholar 

  • Goessl C., Plaschke J, Pistorius S., Hahn M., Frank S., Hampl M. et al. 1997 An intronic germline transition in the HNPCC gene hMSH2 is associated with sporadic colorectal cancer. Eur. J. Cancer 33, 1869–1874.

    CAS  PubMed  Google Scholar 

  • Hainaut P. and Hollstein M. 2000 P53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 77, 81–137.

    CAS  PubMed  Google Scholar 

  • Hao W., Xu X., Shi H., Zhang C. and Chen X. 2018 No association of TP53 codon 72 and intron 316-bp duplication polymorphisms with breast cancer risk in Chinese Han women: new evidence from a population-based case-control investigation. Eur. J. Med. Res. 23, 47.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Hsieh L. L., Huang T. H., Chen I. H., Liao C. T., Wang H. M., Lai C. H. et al. 2005 p53 polymorphisms associated with mutations in and loss of heterozygosity of the p53 gene in male oral squamous cell carcinomas in Taiwan. Br. J. Cancer 92, 30–35.

    CAS  PubMed  Google Scholar 

  • Huang Z. H., Hua D., Li L. H. and Zhu J. D. 2008 Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy. J. Cancer Res. Clin. Oncol. 134, 1129–1134.

    CAS  PubMed  Google Scholar 

  • Hunt C. R., Ramnarain D., Horikoshi N., Iyengar P., Pandita R. K., Shay J. W. et al. 2013 Histone modifications and DNA double-strand break repair after exposure to ionizing radiations. Radiat. Res. 179, 383–392.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kaur S., Sambyal V., Guleria K., Manjari M., Sudan M., Uppal M. S. et al. 2014 Analysis of TP53 polymorphisms in North Indian sporadic esophageal cancer patients. Asian Pac. J. Cancer Prev. 15, 8413–8422.

    PubMed  Google Scholar 

  • Kim J. G., Sohn S. K., Chae Y. S., Song H. S., Kwon K. Y., Do Y. R. et al. 2009 TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cancer Chemother. Pharmacol. 64, 355–360.

    CAS  PubMed  Google Scholar 

  • Lacerda L. L., Serrano S. V., Mathes A., Rey J. A., Bello M. J. and Casartelli C. 2005 An intronic variant in the TP53 gene in a Brazilian woman with breast cancer. Cancer Genet. Cytogenet. 160, 160–163.

    CAS  PubMed  Google Scholar 

  • Leroy B., Anderson M. and Soussi T. 2014 TP53 mutations in human cancer: database reassessment and prospects for the next decade. Hum. Mutat. 35, 672–688.

    CAS  PubMed  Google Scholar 

  • Levine A. J. 1997 p53, the cellular gatekeeper for growth and division. Cell 88, 323–331.

    CAS  PubMed  Google Scholar 

  • Levine A. J. and Oren M. 2009 The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer 9, 749–758.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Li X., Dumont P., Della Pietra A., Shetler C. and Murphy M. E. 2005 The codon 47 polymorphism in p53 is functionally significant. J. Biol. Chem. 280, 24245–24251.

    CAS  PubMed  Google Scholar 

  • Li Y. and Prives C. 2007 Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 26, 2220–2225.

    CAS  PubMed  Google Scholar 

  • Li Z., Zhang Z., He Z., Tang W., Li T., Zeng Z. et al. 2009 A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers. Cell Res. 19, 519–523.

    CAS  PubMed  Google Scholar 

  • Litviakov N. V., Denisov E. V., Takhauov R. M., Karpov A. B., Skobel’skaja E. V., Vasil’eva E. O. et al. 2010 Association between TP53 gene Arg72Pro polymorphism and chromosome aberrations in human cancers. Mol. Carcinog. 49, 521–524.

    CAS  PubMed  Google Scholar 

  • Mitra S., Sikdar N., Misra C., Gupta S., Paul R. R., Roy B. et al. 2005a Risk assessment of p53 genotypes and haplotypes in tobacco-associated leukoplakia and oral cancer patients from eastern India. Int. J. Cancer 117, 786–793.

    CAS  PubMed  Google Scholar 

  • Mitra S., Misra C., Singh R. K., Panda C. K. and Roychoudhury S. 2005b Association of specific genotype and haplotype of p53 gene with cervical cancer in India. J. Clin. Pathol. 58, 26–31.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Murarasu D., Puiu L., Mihalcea C., Pitica I. M. A., Mambet C., Radu E. L. et al. 2018 Characterization of TP53 polymorphisms in Romanian colorectal cancer patients. Romanian Biotechnol. Lett. 23, 14124–14134.

    CAS  Google Scholar 

  • Murphy M. E. 2006 Polymorphic variants in the p53 pathway. Cell Death Differ. 13, 916–920.

    CAS  PubMed  Google Scholar 

  • Naccarati A., Pardini B., Polakova V., Smerhovsky Z., Vodickova L., Soucek P. et al. 2010 Genotype and haplotype analysis of TP53 gene and the risk of pancreatic cancer: an association study in the Czech Republic. Carcinogenesis 31, 666–670.

    CAS  PubMed  Google Scholar 

  • Osorio A., Martínez-Delgado B., Pollan M., Cuadros M., Urioste M., Torrenteras C. et al. 2006 A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers. Hum. Mutat. 27, 242–248.

    CAS  PubMed  Google Scholar 

  • Patel K. R., Vajaria B. N., Begum R., Shah F. D., Patel J. B., Shukla S. N. et al. 2013 Association between p53 gene variants and oral cancer susceptibility in population from Gujarat, West India. Asian Pac. J. Cancer Prev. 14, 1093–1100.

    PubMed  Google Scholar 

  • Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S. V., Hainaut P. et al. 2007 Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 28, 622–629.

    CAS  Google Scholar 

  • Polakova V., Pardini B., Naccarati A., Landi S., Slyskova J., Novotny J. et al. 2009 Genotype and haplotype analysis of cell cycle genes in sporadic colorectal cancer in the Czech Republic. Hum. Mutat. 30, 661–668.

    CAS  PubMed  Google Scholar 

  • Rodrigues P., Furriol J., Tormo E., Ballester S., Lluch A. and Eroles P. 2013 Epistatic interaction of Arg72Pro TP53 and -710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survival. Mol. Cell Biochem. 379, 181–190.

    CAS  PubMed  Google Scholar 

  • Rogler A., Rogenhofer M., Borchardt A., Lunz J. C., Knoell A., Hofstaedter F. et al. 2011 P53 codon 72 (Arg72Pro) polymorphism and prostate cancer risk: association between disease onset and proline genotype. Pathobiology 78, 193–200.

    CAS  PubMed  Google Scholar 

  • Shi Y. Y. and He L. 2005 SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 15, 97–98.

    CAS  PubMed  Google Scholar 

  • Singamsetty G. K., Malempati S., Bhogadhi S., Kondreddy R., Govatati S., Tangudu N. K. et al. 2013 TP53 alterations and colorectal cancer predisposition in south Indian population: a case-control study. Tumour Biol. 35, 2303–2311.

    PubMed  Google Scholar 

  • Sjalander A., Birgander R., Athlin L., Stenling R., Rutegard J., Beckman L. et al. 1995 P53 germ line haplotype associated with increased risk for colorectal cancer. Carcinogenesis 16, 1461–1464.

    CAS  PubMed  Google Scholar 

  • Sjalander A., Birgander R., Hallmans G., Cajander S., Lenner P., Athlin L. et al. 1996 p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17, 1313–1316.

    CAS  PubMed  Google Scholar 

  • Slee E. A., O’Connor D. J. and Lu X. 2004 To die or not to die: how does p53 decide? Oncogene 23, 2809–2818.

    CAS  PubMed  Google Scholar 

  • Smith M. L., and Fornace A. J., Jr 1996 The two faces of tumor suppressor p53. Am. J. Pathol. 148, 1019–1022.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Suzuki K. and Matsubara H. 2011 Recent advances in p53 research and cancer treatment. J. Biomed. Biotechnol. 2011, 978312.

    PubMed  PubMed Central  Google Scholar 

  • Tommiska J., Eerola H., Heinonen M., Salonen L., Kaare M., Tallila J. et al. 2005 Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin. Cancer Res. 11, 5098–5103.

    CAS  PubMed  Google Scholar 

  • Toyama T., Zhang Z., Nishio M., Hamaguchi M., Kondo N., Iwase H. et al. 2007 Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res. 9, R34.

    PubMed  PubMed Central  Google Scholar 

  • Trifa F., Karray-Chouayekh S., Mabrouk I., Baccouche S., Khabir A., Sellami-Boudawara T. et al. 2010 Haplotype analysis of p53 polymorphisms: Arg72Pro, Ins16bp and G13964C in Tunisian patients with familial or sporadic breast cancer. Cancer Epidemiol. 34, 184–188.

    CAS  PubMed  Google Scholar 

  • Trifonova E. A., Spiridonova M. G., Gabidulina T. V., Urnov F. D., Puzyrev V. P. and Stepanov V. A. 2012 Analysis of the MTHFR gene linkage disequilibrium structure and association of polymorphic gene variants with coronary atherosclerosis. Genetika 48, 1207–1220.

    CAS  PubMed  Google Scholar 

  • Voropaeva E. N., Voevoda M. I., Pospelova T. I. and Maksimov V. N. 2014 Linkage disequilibrium and haplotypes of rs1042522, rs1625895 and rs17878362 gene TP53 markers in patients with diffuse large B-cell lymphoma. Mol. Biol. (Mosk) 48, 763–767.

    CAS  Google Scholar 

  • Vymetalkova V., Soucek P., Kunicka T., Jiraskova K., Brynychova V., Pardini B. et al. 2015 Genotype and haplotype analyses of TP53 gene in breast cancer patients: association with risk and clinical outcomes. PLoS One 10, e0134463.

    PubMed  PubMed Central  Google Scholar 

  • Wade M., Li Y. C. and Wahl G. M. 2013 MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat. Rev. Cancer 13, 83–96.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Wang-Gohrke S., Weikel W., Risch H., Vesprini D., Abrahamson J., Lerman C. et al. 1999 Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. Br. J. Cancer 81, 179–183.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Whibley C., Pharoah P. D. and Hollstein M. 2009 p53 polymorphisms: cancer implications. Nat. Rev. Cancer 9, 95–107.

    CAS  PubMed  Google Scholar 

  • Wu X., Zhao H., Amos C. I., Shete S., Makan N., Hong W. K. et al. 2002 p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J. Natl. Cancer Inst. 94, 681–690.

    CAS  PubMed  Google Scholar 

  • Xinarianos G., Liloglou T., Prime W., Sourvinos G., Karachristos A., Gosney J. R. et al. 2002 p53 status correlates with the differential expression of the DNA mismatch repair protein MSH2 in non-small cell lung carcinoma. Int. J. Cancer 101, 248–252.

    CAS  PubMed  Google Scholar 

  • Xu Y., Yao L., Ouyang T., Li J., Wang T., Fan Z. et al. 2005 p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin. Cancer Res. 11, 7328–7333.

    CAS  PubMed  Google Scholar 

  • Zha Y., Gan P., Liu Q. and Yao Q. 2016 TP53 Codon 72 polymorphism predicts efficacy of paclitaxel plus capecitabine chemotherapy in advanced gastric cancer patients. Arch. Med. Res. 47, 13–18.

    CAS  PubMed  Google Scholar 

  • Zhang G., Xu Q., Liu J., Lv Z., Lu Y., Yang H. et al. 2019 Five P53 SNPs involved in low rectal cancer risk and prognosis in a Chinese population. J. Cancer 10, 1772–1780.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank the study participants for taking part in this study. This study was supported by the DST grant SR/S0/HS/0089/2010 sanctioned to VS and KG.

Author information

Authors and Affiliations

  1. Human Cytogenetics Laboratory, Department of Human Genetics, Guru Nanak Dev University, Amritsar, 143 005, India

    Vasudha Sambyal, Sukhpreet Kaur & Kamlesh Guleria

  2. Department of Pathology, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, 143 005, India

    Mridu Manjari

  3. Department of Surgery, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, 143 005, India

    Manjit Singh Uppal & Neeti Rajan Singh

  4. Department of Radiotherapy, Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, 143 005, India

    Meena Sudan

Authors
  1. Vasudha Sambyal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sukhpreet Kaur
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mridu Manjari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Manjit Singh Uppal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Neeti Rajan Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Meena Sudan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kamlesh Guleria
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kamlesh Guleria.

Additional information

Corresponding editor: B. K. THELMA

Corresponding editor: B. K. Thelma

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 22 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sambyal, V., Kaur, S., Manjari, M. et al. Linkage disequilibrium and haplotypes of five TP53 polymorphisms in oesophageal cancer patients. J Genet 99, 62 (2020). https://doi.org/10.1007/s12041-020-01224-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12041-020-01224-8

Keywords

Search

Navigation